Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentina Vanini

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Frontiers in Immunology|July 21, 2018
Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis LesionsThomas Blauenfeldt, Linda Petrone, Franca Del Nonno, et al.
Vaccines|May 7, 2025
Anti-SARS-CoV-2 B and T-Cell Immune Responses Persist 12 Months After mRNA Vaccination with BNT162b2 in Systemic Lupus Erythematosus Patients Independently of Immunosuppressive TherapiesMario Ferraioli, Alessandra Aiello, Immacolata Prevete, et al.
Frontiers in Immunology|May 13, 2021
PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active DiseaseGermana Grassi, Valentina Vanini, Federica De Santis, et al.
Frontiers in Neurology|June 17, 2022
Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple SclerosisLinda Petrone, Carla Tortorella, Alessandra Aiello, et al.
The Journal of Infection|February 27, 2021
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapyLinda Petrone, Elisa Petruccioli, Tonino Alonzi, et al.
Iscience|January 2, 2023
Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19Louise Pierneef, Anouk van Hooij, Danielle de Jong, et al.
Frontiers in Immunology|January 28, 2025
Specific immune response to <i>M. tuberculosis</i> and ability to <i>in vitro</i> control mycobacterial replication are not impaired in subjects with immune-mediated inflammatory disease and tuberculosis infectionChiara Farroni, Anna Maria Gerarda Altera, Andrea Salmi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 25, 2022
Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4<sup>+</sup> and CD8<sup>+</sup> T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assayAlessandra Aiello, Andrea Coppola, Valentina Vanini, et al.
Frontiers in Immunology|September 23, 2022
Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapySaeid Najafi-Fard, Elisa Petruccioli, Chiara Farroni, et al.
Plos One|October 12, 2020
Multicenter analysis of sputum microbiota in tuberculosis patientsClaudia Sala, Andrej Benjak, Delia Goletti, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|July 21, 2018
Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis LesionsThomas Blauenfeldt, Linda Petrone, Franca Del Nonno, et al.
Vaccines|May 7, 2025
Anti-SARS-CoV-2 B and T-Cell Immune Responses Persist 12 Months After mRNA Vaccination with BNT162b2 in Systemic Lupus Erythematosus Patients Independently of Immunosuppressive TherapiesMario Ferraioli, Alessandra Aiello, Immacolata Prevete, et al.
Frontiers in Immunology|May 13, 2021
PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active DiseaseGermana Grassi, Valentina Vanini, Federica De Santis, et al.
Frontiers in Neurology|June 17, 2022
Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple SclerosisLinda Petrone, Carla Tortorella, Alessandra Aiello, et al.
The Journal of Infection|February 27, 2021
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapyLinda Petrone, Elisa Petruccioli, Tonino Alonzi, et al.
Iscience|January 2, 2023
Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19Louise Pierneef, Anouk van Hooij, Danielle de Jong, et al.
Frontiers in Immunology|January 28, 2025
Specific immune response to <i>M. tuberculosis</i> and ability to <i>in vitro</i> control mycobacterial replication are not impaired in subjects with immune-mediated inflammatory disease and tuberculosis infectionChiara Farroni, Anna Maria Gerarda Altera, Andrea Salmi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 25, 2022
Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4<sup>+</sup> and CD8<sup>+</sup> T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assayAlessandra Aiello, Andrea Coppola, Valentina Vanini, et al.
Frontiers in Immunology|September 23, 2022
Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapySaeid Najafi-Fard, Elisa Petruccioli, Chiara Farroni, et al.
Plos One|October 12, 2020
Multicenter analysis of sputum microbiota in tuberculosis patientsClaudia Sala, Andrej Benjak, Delia Goletti, et al.
Pageof 7